Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.
Chen
Andy I
AI
Division of Oncology, Stanford University Medical Center, Stanford, California.
Advani
Ranjana H
RH
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001087:Arabinonucleosides / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004167:Diphtheria Toxin / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011480:Protease Inhibitors / Q000627:therapeutic use; D011684:Purine Nucleosides / Q000627:therapeutic use; D011683:Purine-Nucleoside Phosphorylase / Q000037:antagonists & inhibitors; D011744:Pyrimidinones / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D004167:Diphtheria Toxin; D056572:Histone Deacetylase Inhibitors; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011480:Protease Inhibitors; D011684:Purine Nucleosides; D011744:Pyrimidinones; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; D003841:Deoxycytidine; C078456:denileukin diftitox; D000074323:Alemtuzumab; C113101:forodesine; C104457:nelarabine; D011683:Purine-Nucleoside Phosphorylase; C520522:zanolimumab; D000093542:Gemcitabine